Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07314346 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 16, 2026 (before its estimated August 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary and study completion pushed from Jun 2026 to Aug 2026v3
  2. Recruitment opened
    • Study sites: 1 to 3
    • Primary and study completion dates: May 29, 2026 to Jun 2026
    • Start date changed from estimate of Dec 2025 to Jan 7, 2025
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Drug-drug interaction study between Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone
Trial Details
NCT Number NCT07314346
Lead Sponsor Atea Pharmaceuticals, Inc.
Conditions
(from sponsor)		 Healthy Volunteer Study
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov